After invasive ductal carcinoma, invasive lobular carcinoma (ILC) is the most frequent breast cancer and accounts for nearly 15% of all breast cancers (BC). Doxorubicin (DXR) is a very effective chemotherapeutic drug utilized to treat BC but induces drug resistance and severe side effects. Recently, liposomes have gained popularity as effective tumor microenvironment (TME) modulatory anticancer agents for various malignancies, including BC. This study propose a liposomal-DXR combination to produce an immune-responsive regulatory effect on competing endogenous RNAs (ceRNAs) through alteration in TME and investigate the immunological and anticancer impact of liposomal-DXR combination via regulation of ceRNAs and immune regulatory cytokines at BC cells.